Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Biovian","sponsor":"ANL Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ANLBIO Selected Biovian for Manufacturing of AAV-based product for The Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"FINLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Biovian

    Menu

    Biovian

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Biovian

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Finland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ANLBIO Selected Biovian for Manufacturing of AAV-based product for The Treatment of Alzheimer’s Disease

              Details:

              The agreement covers process development for ANLBIO’s gene therapy vector, ANL-101, followed by 200 L scale production. The manufacturing part of the agreement covers upscaling of the process to working volume of 100s of liters and subsequent manufacture facilities.

              Lead Product(s): ANL-101

              Therapeutic Area: Neurology Product Name: ANL-101

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Recipient: ANL Bio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement February 18, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY